Company Analysis
Sign in

Century Therapeutics, Inc. (IPSC)

Nasdaq: IPSC · Biological Products, (No Diagnostic Substances) · Philadelphia, PA · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.7
◀ Past 4.6● Present 6.2▶ Future 6.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

9 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Century Therapeutics, Inc.’s names, not what it holds today.

Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 2 in 2023
Applications published
30
9 of them in 2025
Names they are printed under
4
its own name, a subsidiary
By yearGrantedApplications published
'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology5
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Century Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
12 published
Gadeta B.V. a subsidiary
named as the applicant on its applications, in NL
0 granted
12 published
Century Therapeutics, Inc. its own name
US, as the owner printed on each patent
4 granted
5 published
GADETA B.V. a subsidiary
NL, as the owner printed on each patent
5 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 8, 202512,269,888Artificial cell death polypeptide for chimeric antigen receptor and uses thereofBiotechnologyCentury Therapeutics, Inc.
Jan 30, 202411,883,432Chimeric antigen receptor system with adaptable receptor specificityBiotechnologyCentury Therapeutics, Inc.
May 30, 202311,661,459Artificial cell death polypeptide for chimeric antigen receptor and uses thereofBiotechnologyCentury Therapeutics, Inc.
Mar 7, 202311,596,654Human leukocyte antigen restricted gamma delta T cell receptors and methods of use thereofBiotechnologyGADETA B.V.
Aug 2, 202211,401,246Triazole glycolate oxidase inhibitorsOrganic fine chemistryCentury Therapeutics, Inc.
Nov 9, 202111,166,984Method for identifying δT-cell (or γT-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective responseBiotechnologyGADETA B.V.
Mar 3, 202010,578,609Nucleic acid molecules encoding combinatorial gamma 9 delta 2 T-cell receptors and methods of use thereof to treat cancerAnalysis of biological materialsGADETA B.V.
Jun 18, 201910,324,083Methods of treating cancer in a subject by administering a composition comprising gamma 9 delta 2 T-cell receptorsAnalysis of biological materialsGADETA B.V.
Feb 13, 20189,891,211Gamma 9 delta 2 T cell receptorsAnalysis of biological materialsGADETA B.V.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0368716DELTA T-CELL OR GAMMA T-CELL RECEPTOR CHAINS OR PARTS THEREOF THAT MEDIATE AN ANTI-TUMOUR OR ANTI-INFECTIVE RESPONSEAnalysis of biological materialsGadeta B.V.
Nov 27, 20252025/0360210IMMUNOEFFECTOR CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS GENETICALLY ENGINEERED WITH MEMBRANE BOUND IL12 AND USES THEREOFPharmaceuticalsCentury Therapeutics, Inc.
Nov 13, 20252025/0345425CELLS ENGINEERED WITH AN HLA-E AND HLA-G TRANSGENEBiotechnologyCentury Therapeutics, Inc.
Oct 16, 20252025/0319184CHIMERIC, TRANSMEMBRANE PROTEINS WITH BIDIRECTIONAL SIGNALLING ACTIVITYMedical technologyGadeta B.V.
Mar 20, 20252025/0090582GENETICALLY ENGINEERED CELLS HAVING ANTI-CD133 / ANTI-EGFR CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOFBiotechnologyCentury Therapeutics, Inc.
Feb 27, 20252025/0066728Compositions and Methods for Generating Gamma-Delta T Cells from Induced Pluripotent Stem CellsBiotechnologyCentury Therapeutics, Inc.
Feb 27, 20252025/0064934GENETICALLY ENGINEERED CELLS HAVING ANTI-CD19 / ANTI-CD22 CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOFMedical technologyCentury Therapeutics, Inc.
Feb 20, 20252025/0059286ARTIFICIAL CELL DEATH POLYPEPTIDE FOR CHIMERIC ANTIGEN RECEPTOR AND USES THEREOFBiotechnologyCentury Therapeutics, Inc.
Feb 6, 20252025/0043010Method for identifying deltaT-cell (or gammaT-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective responseBiotechnologyGadeta B.V.
Jul 4, 20242024/0216429CHIMERIC ANTIGEN RECEPTOR SYSTEM WITH ADAPTABLE RECEPTOR SPECIFICITYBiotechnologyCentury Therapeutics, Inc.
What it applied for, 2024 to 2025: Biotechnology 6 · Medical technology 3 · Pharmaceuticals 2 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton IPSC · research, not advice